ENDRA Life Sciences Reports No Revenue and Reduced Net Loss in Q2 2025

ENDRA Life Sciences Inc. reported its financial results for the second quarter and first half of 2025, revealing a continued focus on the development of its TAEUS technology, which is designed for accurate liver fat measurement. The company recorded no revenue during the three and six months ended June 30, 2025, consistent with the same periods in 2024. The net loss for the second quarter was $1.23 million, a significant reduction from a net loss of $2.23 million in the prior year. For the first half of 2025, the net loss was $2.26 million, down from $5.00 million in the same period of 2024.

Total operating expenses for the second quarter of 2025 were $1.30 million, a decrease of 42% compared to $2.23 million in the same quarter of 2024. This reduction was primarily driven by lower research and development expenses, which fell to $381,061 from $716,366 year-over-year, as the company shifted its focus towards clinical trials and commercialization efforts. Sales and marketing expenses also decreased by 58% to $68,834, reflecting a restructuring of the sales operations initiated in 2024. General and administrative expenses were reduced by 37% to $851,195, attributed to lower wage-related costs and professional fees.

ENDRA's balance sheet as of June 30, 2025, showed total assets of $2.81 million, down from $4.45 million at the end of 2024. Current assets decreased significantly, primarily due to a reduction in cash, which stood at $1.81 million compared to $3.23 million at the end of the previous year. Total liabilities also decreased to $1.33 million from $1.89 million, with a notable reduction in long-term debt, particularly in warrant liabilities, which fell to $328,610 from $799,284.

The company continues to face challenges in securing adequate financing to support its operations and product development. As of June 30, 2025, ENDRA had an accumulated deficit of $105.7 million and indicated that it would require additional capital to fund ongoing operations and commercialization efforts. The management is exploring various financing options, including equity sales and potential collaborations, to ensure the continuation of its business activities. The outlook remains cautious, with the company emphasizing the need for further funding to achieve its strategic goals and maintain operations.